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ercutaneous Closure of
he Left Atrial Appendage
Major Step Forward*
orst Sievert, MD, Yves L. Bayard, MD
rankfurt, Germany
trial fibrillation is a common cardiac arrhythmia with a
igher prevalence in the elderly population. It is more
requent in men than in women at all ages (1). It might
ause a reduced cardiac output and formation of atrial
hrombi, especially in the left atrial appendage (2). Atrial
brillation is associated with a 5-fold increased risk for
troke and embolism (3) and accounts for as much as
ne-sixth of all ischemic strokes (4). These strokes tend to
e more severe than cerebral embolisms caused by other
ources, probably due to the larger size of thrombi in atrial
brillation (5,6).
See page 594
Several randomized studies, such as the AFFIRM (Atrial
ibrillation Follow-up Investigation of Rhythm Manage-
ent) and the RACE (Rate Control versus Electrical
ardioversion for Persistent Atrial Fibrillation Study) trials,
ave demonstrated the benefit of anticoagulation treatment
n both rhythm and rate controlled atrial fibrillation pa-
ients. With a stroke risk reduction of almost 70%, antico-
gulation is highly effective in preventing embolic events in
trial fibrillation patients and is superior to other pharma-
ological approaches (7). Compared with aspirin, oral anti-
oagulation reduces the risk of stroke by 45%. However,
nticoagulation might increase the risk of major bleeding by
pproximately 70% compared with aspirin, accounting for
evere bleedings in up to 2.3% of patients/year (8). Other
isadvantages of anticoagulation therapy are its narrow
herapeutic range, pharmacological and food interactions,
nd the need for frequent monitoring and dose adjustments.
hese might be some of the reasons why only 54% of all
igh-risk patients who are eligible for oral anticoagulation
herapy actually receive warfarin (9). A review of the Food
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the CardioVascular Center Frankfurt, Sankt Katharinen, Frankfurt,P
ermany. Dr. Sievert is a principal investigator of the PLAATO Studies and
nvestigator of the PROTECT AF Study.nd Drug Administration Surveillance and Epidemiology
ffice showed that warfarin was among the top 10 drugs
ith the largest number of serious adverse event reports
rom the year 1990 to 2000 (10). Furthermore, U.S. death
ertificates indicate that anticoagulants ranked first in 2003
nd 2004 in the number of total mentions of deaths for
rugs causing adverse effects in therapeutic use.
The first surgical attempt to remove the left atrial
ppendage as a possible source for thromboembolic event
as made by Madden (11) in 1948.
In the “Maze” operation introduced by Cox (12), several
mall incisions are made in the atria to interrupt atrial
brillation reentry pathways. In a report of 197 patients who
nderwent the Maze procedure, the mean rate of freedom
rom atrial fibrillation was 89% after 10 years of follow-up
13). Despite these good results, the Maze procedure is not
ery commonly used, because it is complicated and time-
onsuming. Operations that were modified from the origi-
al Maze procedure were shown to be less effective than the
riginal procedure (14). Complications of the Maze opera-
ion include atrial dysfunction due to extensive injury to the
trial walls and different types of atrial arrhythmias as a
ossible consequence of partial denervation of the sympa-
hetic and parasympathetic systems of the heart. Most
mportantly, it does not reduce the risk of embolic events, so
atients have to continue with anticoagulation therapy.
Nowadays, surgical obliteration or resection of the left
trial appendage is usually not performed as a stand-alone
rocedure because of its invasive character. Besides, it might
ot prevent thromboembolism from the structure depend-
bly, because it is frequently incomplete (15). However,
urgical ligation of the left atrial appendage is part of the
aze procedure and recommended by the American Col-
ege of Cardiology and the American Heart Association
uidelines during mitral valve surgery.
Why attempt device closure of the left atrial appendage?
meta-analysis of several echocardiographic, surgical, and
utopsy studies of Blackshear et al. (2) revealed that more
han 90% of left atrial thrombi in patients with nonrheu-
atic AF form in the left atrial appendage. Catheter closure
f this structure is a logical and minimally invasive method
o exclude the left atrial appendage from circulation and
hereby prevent cardioembolic events. Basic principles of
his technique are similar to other interventions in structural
eart disease. So far, transcatheter closure of the left atrial
ppendage has only been performed in patients who were
ot eligible for long-term anticoagulation treatment with
arfarin.
In 2001, the first percutaneous left atrial appendage
cclusion was performed with a dedicated device, the
LAATO (Percutaneous Left Atrial Appendage Trans-
atheter Occlusion) occluder (16). The nonrandomized
LAATO Multicenter Studies including sites in the U.S.
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Editorial Comment
602nd in Europe have demonstrated feasibility and short-term
afety of left atrial appendage closure (17).
In this issue of JACC: Cardiovascular Interventions, Block
t al. (18) report the first long-term results after transcath-
ter left atrial appendage occlusion with the PLAATO
evice in 64 patients enrolled in the former PLAATO
ulticenter study. Their findings are encouraging: only 1
ajor adverse event (tamponade) was related to the proce-
ure. No other procedure-related major adverse event oc-
urred during follow-up of up to 5 years. When compared
ith the estimated risk for stroke according to the
HADS2 score, the actual stroke rate in a mean follow-up
ime of 3.8 years was almost cut in half.
Despite promising results with transcatheter closure with
he PLAATO device, there has never been a randomized
rial versus best medical treatment to prove this trend. The
andomization study was successfully conducted with an-
ther device: the Watchman left atrial appendage filter. On
his year’s American College of Cardiology congress, it was
eported to be noninferior to anticoagulation therapy re-
arding stroke risk reduction.
One might argue that the obvious benefit of the proce-
ure regarding stroke reduction might be outweighed by
ong-term complications. However, to date we do not have
ata supporting this.
Given the results of the PROTECT AF (WATCH-
AN Left Atrial Appendage System for Embolic PRO-
ECTion in Patients With Atrial Fibrillation) trial and the
urrent long-term follow-up report with the PLAATO
evice, left atrial appendage occlusion has done a major step
orward.
eprint requests and correspondence: Dr. Horst Sievert, Car-
ioVascular Center Frankfurt, Seckbacher Landstrasse 65, 60389
rankfurt, Germany. E-mail: HorstSievertMD@aol.com.
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